Sentences with phrase «vaccine study center»

Changes in Bordetella are one likely factor in pertussis's rebound, agrees Henry Shinefield, co-director of the Kaiser Permanente Vaccine Study Center in Oakland, California.

Researchers at the Kaiser Permanente Vaccine Study Center in Oakland, Calif., studied the medical records of mothers who gave birth to babies between 2010 and 2015.

«This study demonstrates that despite high rates of Tdap vaccination, the growing number of adolescents who have received only the newer acellular pertussis vaccines continue to be at higher risk of contracting whooping cough and sustaining epidemics,» said lead author Nicola Klein, MD, PhD, co-director of the Kaiser Permanente Vaccine Study Center.

The new formula's reduced effectiveness is most likely driving the recent epidemics of pertussis, says the study's lead author, Nicola Klein, co-director of Kaiser Permanente Vaccine Study Center in Oakland, Calif..

Not exact matches

«Even with the new immunological studies, we can't tell what's special about the whole - cell vaccine that makes it better,» says Kathryn Edwards, the director of the Vanderbilt University School of Medicine Vaccine Research vaccine that makes it better,» says Kathryn Edwards, the director of the Vanderbilt University School of Medicine Vaccine Research Vaccine Research Center.

«Based on epidemiological studies, the 9vHPV vaccine could prevent approximately 90 percent of cervical cancer, 90 percent of HPV - related vulvar and vaginal cancer, 70 to 85 percent of high - grade cervical disease in females, and approximately 90 percent of HPV - related anal cancer and genital warts in males and females worldwide,» explained Anna R. Giuliano, Ph.D., Director of the Center for Infection Research in Cancer at Moffitt.

The researchers, including those from Moffitt Cancer Center, published the final results of a study showing the newest vaccine is highly effective at preventing HPV infection and disease.

«What this study tells us is that if more and more people choose not to get a vaccine,» says Paul Offit, director of the Vaccine Education Center at The Children's Hospital of Philadelphia, «then you'll have bigger and bigger outbreaks.vaccine,» says Paul Offit, director of the Vaccine Education Center at The Children's Hospital of Philadelphia, «then you'll have bigger and bigger outbreaks.Vaccine Education Center at The Children's Hospital of Philadelphia, «then you'll have bigger and bigger outbreaks.»

The multi-center study enrolled 31,989 participants from 126 research centers in the U.S. and Canada during the 2011 - 2012 and 2012 - 2013 influenza seasons in the Northern Hemisphere in order to compare the high - dose trivalent vaccine versus the standard - dose trivalent vaccine in adults over 65 years of age.

A few months later, he was working at the International Center for Genetic Engineering and Biotechnology (ICEGB) in Delhi, studying malaria vaccines.

By studying healthy people, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center, part of the NIH, and colleagues from King's College London have created a reference resource for other scientists.

One goal of the study is to demonstrate the prevalence of H. influenzae in the region, explains Joel Ward, director of the Center for Vaccine Research at the University of California, Los Angeles, and scientific adviser to IVI.

«HPV vaccines could dramatically reduce the incidence of HPV - associated cancers, but uptake of these vaccines is far lower than for other routine childhood and teen immunizations,» said Kevin A. Henry, PhD, an assistant professor in the Department of Geography and Urban Studies at Temple University in Philadelphia and member of Fox Chase Cancer Center's Cancer Prevention and Control program.

«An RSV vaccine with this M2 - 2 deletion could tip the balance toward a better immune response, which is what we predicted based on earlier laboratory studies,» says study leader Ruth A. Karron, MD, director of the Center for Immunization Research and a professor in the Department of International Health at the Bloomberg School.

In a March 2009 study published in Genes and Immunity, researchers at the National Center for Computational Toxicology compared the genetic signatures of 16 people who experienced smallpox vaccine side effects, including fever, rashes and enlarged lymph nodes, to 45 people who did not.

«Although data clearly indicate better immune responses and vaccine efficacy against both genital warts and cervical dysplasia when vaccination occurs before age 14, this study suggests that HPV vaccination may be effective in reducing abnormal Pap test results even after sexual debut,» explained co-author Rebecca Perkins, MD, MSc, assistant professor of Obstetrics and Gynecology at Boston University School of Medicine and a gynecologist at Boston Medical Center.

Researchers led by a team at Duke University identified these immunologic variations by studying blood samples collected from people living with HIV by the NIAID - supported Center for HIV / AIDS Vaccine Immunology (CHAVI).

In the preclinical study, WRAIR and the Beth Israel Deaconess Medical Center tested two Zika virus vaccine candidates: a DNA vaccine developed at Harvard based on a Zika virus strain isolated in Brazil, and a purified inactivated virus vaccine developed at WRAIR based on a Zika virus strain isolated in Puerto Rico.

The Walter Reed Army Institute of Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two Zika vaccine candidates that suggests that an effective human vaccine will be achievable.

«This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,» said David B. Weiner, Ph.D., executive vice president of The Wistar Institute, director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author of the study.

«You certainly can't do a $ 100 million study for every candidate vaccine that appears safe and immunogenic,» says Mark Mulligan, a molecular virologist who heads the vaccine center at Emory University in Atlanta and does human challenges with norovirus and tuberculosis.

Researchers at the Mailman School of Public Health and Columbia University Medical Center studied the impact of text message reminders for the second dose of influenza vaccine required for many young children to protect them against the virus.

A new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV - 1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs.

The studies support the concept of using natural exposure in combination with malaria - fighting drugs to help people build up protection against disease, says malaria vaccine researcher Robert Sauerwein of the Radboud University Nijmegen Medical Center in the Netherlands.

«Currently, there is a lot of focus on the use of antibodies transferred passively or through a vaccine to prevent infection in infants, however this study cautions against that and suggests that broadly neutralizing antibodies may actually aid in enhancing transmission from mother to child,» added Sagar, an attending physician in infectious diseases at Boston Medical Center.

This new work suggests that anti-PD-1 antibodies might be equally effective in treating hepatitis C and other persistent human viral infections, says Christopher Walker, PhD, a senior author on the study and director of the Center for Vaccines and Immunity at Nationwide Children's.

The Center has a GMP pilot plant being able to produce recombinant antigens for vaccine formulations, formulation studies with the SSI CAF cased adjuvants is performed in laboratories using qualified equipment and procedures.

Dr. Polonis has coordinated regional labs in Thailand and East Africa for the Duke University Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA - VIMC) funded by the Bill and Melinda Gates Foundation, and is a standing member of the HIV Vaccines Study Section for the Center for Scientific Review at the NIH.

As a member of the Vaccine & Immunotherapy Center he studied accelerated vaccine development and targeted cancer therapies until FebruarVaccine & Immunotherapy Center he studied accelerated vaccine development and targeted cancer therapies until Februarvaccine development and targeted cancer therapies until February 2015.

A phase 2 study of the therapeutic vaccine is currently underway in other centers in patients with recurrent disease to see if it can help extend 12 - month survival.

Its Clinical Trials Center conducts 13 - 15 clinical studies per year, and in December initiated a Phase 2 clinical trial of an Ebola vaccine following its groundbreaking first - in - human testing of the Ebola vaccine that showed efficacy in Guinea last year.

These studies were sponsored by the Vaccine Research Center (VRC), NIAID, NIH.

Padmanee Sharma, M.D., Ph.D., a member of the CRI / Ludwig Cancer Vaccine Collaborative (CVC) at The University of Texas MD Anderson Cancer Center, has conducted innovative studies testing the effects of anti-CTLA-4 checkpoint blockade in the pre-surgical setting.

Researchers in Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases conducted this study.

The products used in the trial were tested in the U.S. prior to the launch of the study in Uganda and were developed by the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID).

Hundreds of volunteers at the Vaccine Center's Hope Clinic took part in this study.

«Our work sheds light on the nature of CD32 as a molecule associated with transcriptionally active HIV and proves that targeting CD32 - positive cells is unlikely to hit the HIV latent reservoir,» said Mohamed Abdel - Mohsen, Ph.D., assistant professor in The Wistar Institute Vaccine & Immunotherapy Center and first author of the study.

«Now that we know that [the difference] exists, it contributes to our understanding of why the vaccine is not effective in all cases and informs future vaccine development efforts,» said Dr. Dan Neafsey, associate director of the Genomic Center for Infectious Diseases at the Broad and co-first author of the study.

Silvestri's colleagues on this study include Maud Mavigner, PhD, Yerkes and Emory Vaccine Center, Ann Chahroudi, MD, PhD, Emory University School of Medicine (EUSOM) Department of Pediatrics, and Leslie Kean, MD, PhD, and Benjamin Watkins, MD, EUSOM Department of Surgery.

This vaccine prototype is today being studied by Cancer Center researchers in clinical trials for kidney, prostate, and pancreatic cancers.

«This study allowed us to evaluate the protective efficacy of several prime - boost vaccine combinations, and these data will help guide the advancement of the most promising candidates into clinical trials,» noted lead author Dr. Dan Barouch of Beth Israel Deaconess Medical Center at Harvard Medical School and the Ragon Institute of MGH, MIT, and Harvard.

Now that I am part of a Vaccine Research Center (VRC) vaccine study, it enhances that altruistic feeling even more, knowing that my participation may someday save millions ofVaccine Research Center (VRC) vaccine study, it enhances that altruistic feeling even more, knowing that my participation may someday save millions ofvaccine study, it enhances that altruistic feeling even more, knowing that my participation may someday save millions of lives.

The nanoparticle vaccine technology used in the study has been licensed by Parvus Therapeutics, Inc., a biotechnology company arising from the University Technology International LP, the technology transfer and commercialization center for the University of Calgary.

Although there are no clinical studies proving its efficacy, Dr. Matthew Brennecke, a board certified naturopathic doctor practicing at the Rocky Mountain Wellness Center in Fort Collins, Colo., told Medical Daily in an email, «A common theory is that honey acts like a natural vaccine.»

«This is an important study that highlights the ability of even a modest vaccine to substantially save lives during flu season,» said Dr. Amesh Adalja, a senior scholar with the Johns Hopkins Center for Health Security.

Genetic Vaccine Helps Immune System Researchers Dr. H. Kim Lyerly and Eli Gilboa from Duke University's Center for Genetic and Cellular Therapies in Durham, NC, are studying the safety and effectiveness of a new immune system therapy called a genetic vVaccine Helps Immune System Researchers Dr. H. Kim Lyerly and Eli Gilboa from Duke University's Center for Genetic and Cellular Therapies in Durham, NC, are studying the safety and effectiveness of a new immune system therapy called a genetic vaccinevaccine.

There is some compelling evidence coming from a study conducted at The Center for Companion Animal Studies at Colorado State University that shows that the common FVRCP (feline viral rhinotracheitis, calicivirus and paneleukopenia) vaccine may cause long - term damage to cats» kidneys that increases with every booster.